The cluster suggests a shared positive thesis on Vir's pipeline, but the 45-day 13F lag means positions may already be stale. Watch for upcoming clinical data or partnership announcements that could have driven this accumulation. The lack of insider buying reduces conviction, consider waiting for a catalyst before initiating a position.
VIR drugs
VIR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $8.89entry
- T+1 · 3mo ago +0.45%α +0.77% · $8.93
- T+5 · 3mo ago +5.62%α +5.67% · $9.39
- T+20 · 2mo ago +25.76%α +26.67% · $11.18
- T+60 · 14d ago +26.21%α +28.63% · $11.22
How similar events traded
Executive Summary
Six institutional investors added a net $44.9M to Vir Biotechnology in Q2 2026, led by State Street (+$37.6M) and Pictet Asset Management (+$6.6M), while only one small seller trimmed. The cluster signals growing institutional confidence, though the absence of insider buying and the passive nature of the largest buyer temper conviction.
Key Financial Metrics
Institutional Positions
Net institutional flow: $44.9M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| State Street | ADD | +39.5% | $101.5M | $37.6M |
| Pictet Asset Management Holding | ADD | +31.9% | $19.9M | $6.6M |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Mitsubishi Ufj Asset Management Co. | TRIM | -38.5% | $383.0K | -$115.0K |
Key Facts
- 6 institutional buyers added $45.0M in net new value; 1 seller trimmed $115K
- State Street (passive) added 2.82M shares worth $37.6M, now holding $101.5M
- Pictet Asset Management added 472.5K shares worth $6.6M, now holding $19.9M
- No open-market insider buying detected (confluence score 21/100, divergent)
- Net buying represents ~3% of VIR's $1.5B market cap
Financial Impact
Net institutional buying of $44.9M across 6 buyers, with State Street contributing $37.6M of the total
Risk Factors
- Largest buyer (State Street) is a passive index fund, reducing signal strength
- No insider buying to corroborate institutional conviction
- 13F filings are 45 days stale; positions may have been unwound
- Biotech sector risk: pipeline failures or regulatory setbacks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-VIR-2026-Q2 |
Track record
36 reports on VIR
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 4 of 8 went positive at some point.
Filters
- Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
- Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 settles Nov 23
- Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 settles Nov 20
- Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 ▼ −29.79% −28.10% vs SPY
- Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 ▲ +29.79% +28.10% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 ▲ +9.98% +6.69% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 ▲ +17.20% +17.79% vs SPY
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 ▲ +24.05% +23.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers